Christian brings over 10 years of international Life Science Venture Capital and deal making experience to the DDF.
Christian joined the DDF as Partner in 2019.
DDF Portfolio Board Roles
LoQus 23, TranSINE
Christian joins the DDF from Wellington Partners Life Sciences, a leading European venture capital firm investing in early- and growth-stage life science companies. In his role as Principal, Christian helped to raise Wellington’s fifth-generation fund which was closed at €210 million, making it the largest life science dedicated fund raised by Wellington Partners to date. While at Wellington Partners Life Sciences, he was focused on investing in opportunities covering novel therapeutics and medical devices. Christian served on the Boards of TRiCares GmbH and Uromems SAS. Prior to joining Wellington, Christian was as a Senior Investment Manager with High-Tech Gründerfonds, Europe’s leading seed fund with €896 million under management. There, Christian completed and led the investments in nine seed- and early-stage companies, including Amal Therapeutics SA (acquired by Boehringer Ingelheim in 2019 for up to € 325 million), Rigontec GmbH (acquired by MSD in 2017 for up to € 464 million) and Senostic GmbH, a German diagnostic company active in the field of neurodegenerative disorders. During the course of his PhD, Christian was supporting the Life Science Team of Atlas Venture in Munich.
Christian obtained his MSc degree in Molecular Biotechnology from the Technical University of Munich and was awarded a PhD with distinction in Medical Science and Technology from the Technical University of Munich for his work on patient-specific induced pluripotent stem cells. The key articles generated in the context of his PhD were published in the New England Journal of Medicine, EMBO Molecular Medicine and FASEB Journal and have so far been cited more than 1000 times. In 2013, the thesis was recognized with the “Outstanding PhD thesis award” by the Luxembourg National Research Fund.